The transformation of hepatic stellate cells (HSCs) into myofibroblasts is the defining 31 pathobiology in non-alcoholic steatohepatitis (NASH). Here we show that key NASH 32 factors induce IL-11, which drives an autocrine and ERK-dependent activation loop 33 to initiate and maintain HSC-to-myofibroblast transformation, causing liver fibrosis. 34 IL-11 is upregulated in NASH and Il11ra1-deleted mice are strongly protected from 35 liver fibrosis, inflammation and steatosis in murine NASH. Therapeutic inhibition of 36 IL11RA or IL-11 with novel neutralizing antibodies robustly inhibits NASH pathology 37 in preclinical models and reverses established liver fibrosis by promoting HSC 38 senescence and favourable matrix remodelling. When given early in NASH, IL-11 39 inhibition prevents liver inflammation and steatosis, reverses severe hepatocyte 40 damage and reduces hepatic immune cells and TGFβ1 levels. Our findings show an 41 unappreciated and central role for IL-11 in HSCs and prioritise IL-11 signalling as a 42 new therapeutic target in NASH while revealing an unexpected pro-inflammatory 43 function for IL-11 in stromal immunity. 44 45 65 myofibroblasts with shared features 2,9 . We recently identified Interleukin-11 (IL-11) 66 as a crucial factor for cardiovascular and pulmonary fibroblast-to-myofibroblast 67 transformation 10,11 . To date, there are very limited insights into IL-11 in the liver, 68 where it is reported to have anti-inflammatory activity 12,13 , and it is unknown if HSCs 69 respond to IL-11 at all. Here, we explore the hypothesis that IL-11 plays a role in the 70 transformation of HSCs into myofibroblasts and determine the effects IL-11 signalling 71 in the context of liver inflammation, steatosis and fibrosis in NASH.
Introduction
The global prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated at 47 25% 1 and while NAFLD is reversible it can progress to nonalcoholic steatohepatitis 48 (NASH). NASH is characterized by steatosis-driven inflammation, hepatocyte death 49 and liver fibrosis that can lead to liver failure. Hepatic stellate cells (HSCs) are pivotal 50 in the pathogenesis of NASH and give rise to up to 95% of liver myofibroblasts 2 , 51 which drive the key pathologies in NASH, namely liver fibrosis, inflammation and 52 dysfunction 3-5 . 53 
54
A number of factors are implicated in HSC activation and transformation, including 55 the canonical pro-fibrotic factors transforming growth factor-β1 (TGFβ1) and platelet- 56 derived growth factor (PDGF) 6,7 and also pro-inflammatory factors such as CCL2, 57 TNF⍺ and CCL5 4,7,8 . Perhaps reflecting this redundancy in HSC activation, no single 58 upstream initiating factor has been targeted successfully in NASH. Inhibition of 59 downstream pro-fibrotic targets such as LOXL2 has also been unsuccessful and 60 ongoing clinical trials are focused mostly on inhibiting steatosis. There are no 61 approved drugs for the treatment of NASH. 62 63 Quiescent HSCs are vitamin A storing cells and very distinct from fibroblasts. 64 However, common stimuli activate both cell types and stimulate their transition to 2c). To evaluate the physiological relevance of increased Il-11 levels in NASH, we 126 used a genetic loss-of-function model: the Il-11 receptor subunit alpha deleted 127 mouse (Il11ra1 -/-) 17 . Il11ra1 -/mice on the NASH diet were protected from fibrosis and 128 had lesser steatosis and liver damage and ERK activation ( Fig. 2d-g Supplementary Fig. 2d,e ). Hence, non-canonical and ERK-dependent Il-11 130 signalling, seen previously during fibroblasts-to-myofibroblast transformation 10 , 131 appeared relevant for several distinct aspects of NASH pathobiology. 132 133 In an attempt to target the IL-11 autocrine loop, we genetically immunised mice with 134 IL11RA to generate neutralising anti-IL11RA antibodies. Clones that block fibroblast 135 transformation 10 were identified and clone X209 (IgG1κ, K D = 6nM) that neutralised 136 IL-11 signalling across species was prioritised. X209 blocked fibrogenic protein 137 secretion from HSCs with an IC 50 of 5.4pM. Pharmacokinetic studies using 125 I-X209 138 revealed an in vivo half-life of more than 18 days and strong uptake in the liver 139 ( Supplementary Fig. 3) . To ensure therapeutic specificity for IL-11 signalling and 140 exclude off-target effects, we also developed a neutralising anti-IL-11 antibody 141 (X203) 11 and used both antibodies in downstream studies. 142 143 Initial experiments revealed that both antibodies blocked the TGFβ1-driven transition 144 of HSCs into myofibroblasts ( Fig. 2h, Supplementary Fig. 4a,b,d,e,g) . Follow on 145 studies found that other key NASH stimuli such as PDGF, CCL2, angiotensin II, 146 bFGF or oxidative stress also induce IL-11 secretion from HSCs. And, remarkably, 147 HSC-to-myofibroblast transformation downstream of these various stimuli is 148 consistently dependent on intact IL-11 signalling ( Fig. 2i-k, Supplementary Fig.   149 4c,f,h,i). Thus, IL-11 activity is a critical and universal feature underlying HSC 150 transformation, which has similarities with its activity in fibroblasts 10, 11 . 151 152 We then tested X209 and X203 therapy in vivo and started antibody administration 153 (10 mg kg -1 bi-weekly) after six weeks of NASH diet when IL-11 is strongly 154 upregulated, collagen has accumulated and there is severe steatohepatitis (Fig. 2a-155 c, 3a, Supplementary Fig. 5a ). After four weeks of therapy both antibodies had 156 abolished ERK activation, demonstrating excellent target engagement and coverage. perhaps reflecting end-stage disease (Supplementary Fig. 6c ). Nonetheless, levels 169 of fibrosis and inflammation genes were robustly inhibited by either X203 or X209 170 therapy in this third model ( Supplementary Fig. 6d,e ). Fig. 5g ). To test more fully, if IL-11 inhibition can 219 reverse the fibrotic phenotype beyond the RNA level, we first established severe liver 220 fibrosis and then removed the fibrogenic stimulus and started antibody treatment 221 ( Fig. 4a) . Hepatic collagen content was significantly reversed after three weeks of 222 X203 or X209 treatment and even greater reversal was seen at 6 weeks ( Fig. 4b,  Supplementary Fig. 7a ). In the absence of the dietary trigger, ERK activation 224 spontaneously regressed, which was accelerated by X203 or X209-treatment. 225 Notably, collagen content remained unchanged in IgG control-treated animals for the 226 duration of the experiment ( Fig. 4c, Supplementary Fig. 7b ). As such, anti-IL-11 227 therapies reverse liver fibrosis but this effect is limited in the context of active and 228 severe steatosis where combination therapy with an anti-steatotic may be more 229 effective.
231
Regression of liver fibrosis is associated with lower TIMP and higher MMP levels, 232 which promotes favorable matrix remodelling 3,21 . In keeping with this, X203 or X209 233 treated mice rapidly exhibited strong upregulation of Mmp2 and marked 234 downregulation of Timp1 (Fig. 4d) . Reversal of hepatic fibrosis is favoured when 235 transformed HSCs undergo apoptosis 22 , senescence 23,24 or reversion to an inactive, 236 ACTA2 -ve cellular state 25 . We examined these potential mechanisms and found 237 decreased Acta2, increased senescence markers (p21, p16, and p53) but no change 238 in apoptosis factors with anti-IL-11 therapies ( Fig. 4e, Supplementary Fig. 7c,d) . To Supplementary Fig. 8a,b) . We determined if these effects on inflammation 273 in vivo were related to the action of IL-11 on HSCs and found that IL-11 stimulated 274 HSC secretion of CCL2 whereas IL-11 inhibition blocked CCL2 secretion 275 ( Supplementary Fig. 8c ). This reveals an unappreciated role for IL-11 in stromal 276 immunity and shows that IL-11 neutralisation inhibits paracrine effects of pro- In the HFMCD diet model of NASH, inflammation peaks at six weeks and is then 280 followed by a phase of severe fibrosis (Supplementary Fig. 8d ). We inhibited IL-11 281 signalling early during steatohepatitis and found that livers of X203-and X209-282 treated mice were strikingly less steatotic and had lesser ERK activation ( Fig. 5a,b , 283 Supplementary Fig. 8e-g) . At the molecular level, there was a significant reduction 284 in triglyceride content and lipid droplets in hepatocytes of X203-and X209-treated 285 mice were not apparent ( Fig. 5c,d, Supplementary Fig. 8h ). HFMCD diet induces 286 marked steatohepatitis and liver damage after one week (ALT>700 U L -1 ), which was 287 reversed in a dose-dependent manner to near normal after three weeks of either 288 X203 or X209 treatment ( Fig. 5e,f, Supplementary Fig. 8i ). As expected, X203 or 289 X209 treated mice did not develop fibrosis during the experiment, reaffirming the 290 strong anti-fibrotic effects associated with inhibition of IL-11 signaling ( Fig. 5c ,g, 291 Supplementary Fig. 8h ,j,k).
293
We next performed RNA-seq to profile globally the effects of IL-11 inhibition during 294 steatohepatitis. Unsupervised analyses of these data showed that antibody 295 treatment almost completely reverses the pathological RNA expression signature 296 induced by HFMCD diet (Fig. 5h, Supplementary Fig. 9a,b) . Upregulation of pro-297 fibrotic and pro-inflammatory genes was abolished and lipid metabolism gene 298 expression re-established by anti-IL11RA therapy ( Fig. 5i,j, Supplementary Fig. 9c - Fig. 10 ).
303
Resident macrophages and infiltrating monocytes are important for NASH 304 pathogenesis and a major source of TGFβ1 during disease progression 28 . We 305 examined inflammatory cell populations in the liver during steatohepatitis and 306 observed fewer immune cells in general in X209-treated livers and a specific 307 reduction in Ly6C +ve TGFβ1 +ve cells ( Fig. 5k-m ). TGFβ1 is a major determinant of 308 fibrosis in NASH and can be produced by Kupffer, HSCs and other cells in the liver 5 . 309 Circulating TGFβ1 levels were elevated by HFMCD diet but reduced by X209 310 therapy, which shows that anti-IL11RA therapy is disease-modifying ( Fig. 5n ). the presence of IgG, X203 or X209 antibodies for the times shown in 5a (RNA-seq, n=3/group).
325
Arrows depict the transitions from normal gene expression (NC) to most perturbed gene expression in 326 NASH (HFMCD+IgG), to intermediately restored gene expression (HFMCD+Abs (3w)), to normalised 327 gene expression (HFMCD+Abs(6w)) i, Differential expression heatmap of pro-fibrotic and pro- Recognition of HSCs as the major source for myofibroblasts in the liver 2 prioritizes 340 their transformation as a specific and fundamental target in fibrotic liver diseases. 341 We have previously identified an important function of IL-11 for cardiac and renal 342 fibroblast-to-myofibroblast transformation 10 . We reveal here that IL-11 has non- While earlier publications suggest IL-11 is anti-inflammatory in liver 12,13 , these 360 studies use high-dose recombinant human IL-11 in the mouse, where effects can be 361 non-specific 10 . In contrast, we show here that the biological effect of endogenous Il-362 11 at physiological levels is the opposite: HSC-immune cell crosstalk and activation 363 is IL-11 dependent and inhibition of IL-11 is anti-inflammatory and cytoprotective. 364 Our study demonstrates robust modulation of the immune response by targeting 365 stromal cells through IL-11 inhibition, which was unexpected. This may have 366 implications for other fibro-inflammatory processes where stromal and immune cell 367 functions are closely interlinked, as in tumour microenvironments 30 NASH. This is the first study to demonstrate a role for IL-11 in HSC biology, NASH or 375 stromal immunity and lays the groundwork for future studies to dissect fully the effects of IL-11 signaling in the liver. We believe this presents an exciting opportunity 377 and that our findings may have broad implications across tissues and diseases. Model of streptozotocin-induced diabetes and advanced NASH 678 We engaged contract research organization (CRO) service from SMC Laboratories, 679 Japan to perform this study. Briefly, two-day old male wild-type mice received a 680 single subcutaneous injection of 200 µg streptozotocin (STZ, S1030, Sigma), 681 followed by feeding with high fat diet (HFD32, CLEA Japan) from when they were of Primary human atrial fibroblasts 736 Human atrial fibroblasts were prepared and cultured as described previously 2 .
738
Primary human hepatic stellate cells (HSCs) 739 HSCs (5300, ScienCell) were cultured in stellate cells complete media (5301, 740 ScienCell) on poly-L-lysine-coated culture plates (2 µg cm -2 , 0403, ScienCell).
742
Operetta high throughput phenotyping assay 743 The Operetta phenotyping assay was performed mostly as described previously 3 744 with minor modifications described here: HSCs were seeded in 96-well black 745 CellCarrier plates (PerkinElmer) at a density of 5x10 3 cells per well. myofibroblasts (ACTA2 +ve cells) was measured on the Operetta platform as 800 described above to estimate the neutralization potential of the antibody candidates. 801 In order to block potential trans-signalling effects, antibodies were also screened in 802 the context of hyperIL-11 stimulation of human fibroblasts (200 pg ml -1 ). We detected 803 three specific and neutralizing IL11RA antibodies, of which X209 was taken forward 804 for in vivo studies. The same procedures were performed to obtain a neutralizing 805 antibody that binds to the ligand IL-11, as detailed by Cook et al 3 . Mass cytometry by Time of Flight (CyTOF) 892 Immune cells were isolated from liver as described previously 12 . Liver tissues were 893 minced and digested with 100 µg ml -1 Collagenase IV and 20 U ml -1 DNase I, at 37 o C 894 for 1 h. Following digestion, cells were passed through strainer to obtain single cell 895 suspension and subjected to percoll gradient centrifugation for isolation of immune 896 cells. CyTOF staining was performed as previously described 13 . Cells were thawed 897 and stained with cisplatin (Fluidigm) to identify live cells, followed by staining with 898 metal-conjugated CD45 antibody, for barcoding purpose. After barcoding, cells were 899 stained with metal-conjugated cell surface antibody (Ly6C). Cells were then fixed 900 with 1.6% PFA, permeabilized with 100% methanol, and subjected to intracellular 901 antibody staining (TGFβ1). Cells were finally labeled with DNA intercalator before 902 acquisition on Helios mass cytometer (Fluidigm). For analysis, first live single cells 903 were identified, followed by debarcoding to identify individual samples. Manual 904 gating was performed using Flowjo software (Flowjo, LLC, USA).
RNA-seq analysis

Enzyme-linked immunosorbent assay (ELISA) and colorimetric assays 907
The levels of IL-11 and MMP-2 in equal volumes of cell culture media were 908 quantified using Human IL-11 Quantikine ELISA kit (D1100, R&D Systems) and 
